

XP-002244330

AN - 1994-206342 [25]

AP - JP19920322703 19921106; [Previous Publ. JP6145061] ; JP19920322703
19921106

CPY - FUKO

DC - B04 D13

FS - CPI

IC - A23L1/48 ; A61K35/78 ; A61P17/00 ; A61P35/00

MC - B04-A08C2 B04-A10G B14-H01 B14-N17 D03-F02

M1 - [01] M423 M781 M903 P633 P714 Q211 V600 V631 V752

PA - (FUKO) FUJI SEIYU KK

PN - JP3257091B2 B2 20020218 DW200219 A61K35/78 004pp

→ JP6145061 A 19940524 DW199425 A61K35/78 005pp

PR - JP19920322703 19921106

XA - C1994-094429

XIC - A23L-001/48 ; A61K-035/78 ; A61P-017/00 ; A61P-035/00

AB - J06145061 Drug comprises soybean whey fraction.

- Also claimed is a food comprising the fraction as a functional ingredient.
- USE/ADVANTAGE - The fraction is included in soy bean seed in an amt. of 7-9% of its whole protein, and contains bioactive substances e.g. trypsin inhibitor, haemagglutinin saponin, lipoxygenase, beta-amylase, and protease. Soybean seed is known to show antitumour activity as disclosed in Carcinogenesis (1.469-472, 1980), Carcinogenesis (2. 1213-1214, 1981), etc. The drug and food are useful for the treatment of carcinoma cutaneum and use the whey fraction conventionally seen as industrial waste.
- In an example, soybean whey (200kg) was adjusted to pH5-6, subjected to ultrafiltration (fractionation m.w.: 40000) at 50 deg.C for 20-times concn. adjusted to pH7 with NaOH, and dried by spraying to obtain whey powder (500g). ICR male mice were divided into (A) 20% sepd.-soybean protein diet gp. and (B) (18% SPI + 2% the whey powder) diet gp. and administered for a week. Then, 7,12-dimethylbenzanthracene (initiator) was applied to the mouse back. In a week, phorbol-12-myristate-13-acetate (promoter) was applied to the treatment mice twice a week. After the test period of 14 weeks, the number and the vol. of tumours were measured for comparison (B) whey gp. with (A) SPI gp.. The number of tumour mouse, the number of tumours at a mouse, and the tumour vol. were found to be 47 relative to 80%, 1.6 to 4.7%, and 8 to 50 mm3, showing redn. for (B).
- A mixt. of gelatin (25 pts.wt.), stearic acid (50 pts.wt.), pectin (10 pts.wt.), lactose (400 pts.wt.), potato starch (515 pts.wt.), thiamine (10 pts.wt.), L-ascorbic acid (100 pts.wt.), calcium glycerophosphate (100 pts.wt.), and the whey powder (300 pts.wt.) was granulated to form tablets at 500mg/tablet. The tablets were coated with sugar to prepare health food for the treatment of cutaneous carcinoma and enriched nutrition.(Dwg.0/4)

IW - DRUG TREAT CUTANEOUS CARCINOMA FOOD COMPRISE SOY WHEY FRACTION

IKW - DRUG TREAT CUTANEOUS CARCINOMA FOOD COMPRISE SOY WHEY FRACTION

NC - 001

OPD - 1992-11-06

ORD - 1994-05-24

PAW - (FUKO) FUJI SEIYU KK

**TI - Drug for treatment of cutaneous carcinoma used in food - comprises
soybean whey fraction**